Skip to main content
. Author manuscript; available in PMC: 2021 Jul 15.
Published in final edited form as: Clin Cancer Res. 2020 Oct 21;27(2):554–565. doi: 10.1158/1078-0432.CCR-20-1422

Figure 4.

Figure 4.

Loss of Cav-1 leads to reduced albumin uptake and response to gemcitabine and NP. A. Western blot of apoptotic markers in AsPC-1 cells. Note that levels of cleaved PARP, cleaved caspase 8, 7, and 3 are highest in the Gem(D1)NP(D3) cells. Lysates were collected at 24 hours following start of last treatment. B. MIA-PaCa-2 control (scrambled shRNA) and shCav-1 (shRNA to Cav-1) stably transduced cells were treated with DMSO or gemcitabine (50 nM) for 24 hours followed by a pulse treatment of 0.05% weight/volume of human serum albumin (HSA) in cell culture medium for 1 hour prior to cell lysis. Loss of Cav-1 resulted in reduction in albumin uptake as measured by western blot with a HSA-specific primary antibody. C. Colony forming assays of MIA-PaCa-2 stable control and shCav-1 cells treated with either gemcitabine alone (50 nM), gemcitabine and NP (1 nM) treatment both on day 1 for 24 hours [Gem(D1)NP(D1)], gemcitabine on day 1 and NP on day 2 [Gem(D1)NP(D2)], or gemcitabine on day 1, no treatment on day 2, and NP on day 3 [Gem(D1)NP(D3)]. **p < 0.01, ****p<0.0001.